FY2025 EPS Estimates for MannKind Cut by Leerink Partnrs

MannKind Co. (NASDAQ:MNKD) – Equities researchers at Leerink Partnrs cut their FY2025 earnings estimates for shares of MannKind in a research note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings of $0.16 per share for the year, down from their previous estimate of $0.18. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

A number of other research analysts have also issued reports on MNKD. Wells Fargo & Company started coverage on shares of MannKind in a research report on Friday. They issued an “overweight” rating and a $9.00 target price for the company. Royal Bank of Canada upgraded shares of MannKind from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $7.00 to $10.00 in a research report on Thursday. Leerink Partners began coverage on shares of MannKind in a report on Monday, September 9th. They issued an “outperform” rating and a $8.00 price objective for the company. Oppenheimer upped their target price on MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Finally, StockNews.com cut shares of MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $8.88.

MannKind Price Performance

Shares of NASDAQ MNKD opened at $6.85 on Monday. The business has a 50-day moving average of $6.76 and a 200-day moving average of $6.03. MannKind has a 1-year low of $3.17 and a 1-year high of $7.63. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of 97.86 and a beta of 1.28.

Insider Buying and Selling

In other MannKind news, insider Stuart A. Tross sold 55,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total transaction of $403,700.00. Following the transaction, the insider now directly owns 967,191 shares of the company’s stock, valued at approximately $7,099,181.94. The trade was a 5.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven B. Binder sold 67,536 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.89, for a total transaction of $465,323.04. Following the completion of the sale, the director now directly owns 1,075,026 shares of the company’s stock, valued at approximately $7,406,929.14. This represents a 5.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 190,075 shares of company stock valued at $1,325,587. 3.00% of the stock is owned by company insiders.

Institutional Trading of MannKind

A number of hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of MannKind by 22.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,946 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,816 shares in the last quarter. National Bank of Canada FI increased its stake in MannKind by 14.8% during the 3rd quarter. National Bank of Canada FI now owns 21,553 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 2,783 shares during the period. AQR Capital Management LLC raised its stake in shares of MannKind by 8.1% in the second quarter. AQR Capital Management LLC now owns 42,730 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 3,214 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in MannKind by 3.4% in the second quarter. The Manufacturers Life Insurance Company now owns 101,435 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 3,374 shares during the period. Finally, Commonwealth Equity Services LLC boosted its stake in shares of MannKind by 6.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 68,361 shares of the biopharmaceutical company’s stock valued at $357,000 after buying an additional 3,861 shares during the period. Institutional investors own 49.55% of the company’s stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.